0001237899-20-000010.txt : 20200214 0001237899-20-000010.hdr.sgml : 20200214 20200214161051 ACCESSION NUMBER: 0001237899-20-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200213 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tessier-Lavigne Marc CENTRAL INDEX KEY: 0001437435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20619772 MAIL ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-02-13 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001437435 Tessier-Lavigne Marc 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0 Common Stock 2020-02-13 4 M 0 5000 57.11 A 6830 D Common Stock 2020-02-13 4 S 0 5000 400.03 D 1830 D Common Stock 2020-02-13 4 M 0 9279 50.91 A 11109 D Common Stock 2020-02-13 4 S 0 637 398.71 D 10472 D Common Stock 2020-02-13 4 S 0 800 399.41 D 9672 D Common Stock 2020-02-13 4 S 0 7842 400.16 D 1830 D Non-Qualified Stock Option (right to buy) 50.91 2020-02-13 4 M 0 9279 0.0 D 2021-11-18 Common Stock 9279 0 D Non-Qualified Stock Option (right to buy) 57.11 2020-02-13 4 M 0 5000 0.0 D 2022-01-03 Common Stock 5000 0 D Represents volume-weighted average price of sales of 5,000 shares of Company stock on February 13, 2020 at prices ranging from $400.00 to $400.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Represents volume-weighted average price of sales of 637 shares of Company stock on February 13, 2020 at prices ranging from $398.39 to $398.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Represents volume-weighted average price of sales of 800 shares of Company stock on February 13, 2020 at prices ranging from $399.00 to $399.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Represents volume-weighted average price of sales of 7,842 shares of Company stock on February 13, 2020 at prices ranging from $400.02 to $400.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. /s/**Marc Tessier-Lavigne 2020-02-14